Dopaminergic correlates of metabolic network activity in Parkinson's disease

Human Brain Mapping

Volumn 36, Issue 9, 2015, Pages 3575-3585

  Holtbernd, Florian ^a   Ma, Yilong ^a   Peng, Shichun ^a   Schwartz, Frank ^b   Timmermann, Lars ^b   Kracht, Lutz ^c   Fink, Gereon R ^b,d   Tang, Chris C ^a   Eidelberg, David ^a   Eggers, Carsten ^b,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Brain networks; Dopamine; FDOPA; Parkinson's disease; PET

Indexed keywords

6 FLUORODOPA F 18; DOPAMINE; FLUORODEOXYGLUCOSE F 18; FLUORINE; LEVODOPA; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CAUDATE NUCLEUS; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOTOR DYSFUNCTION; NERVE CELL NETWORK; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PUTAMEN; BRAIN; BRAIN MAPPING; METABOLISM; MIDDLE AGED; NERVE TRACT; SCINTISCANNING;

ADULT; BRAIN; BRAIN MAPPING; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEURAL PATHWAYS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84939466730     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.22863     Document Type: Article

References (40)

1. Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, Mungai F, Marini P, Formiconi AR, Sorbi S, Pupi A (2010): Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. Eur J Nucl Med Mol Imaging 37:537-544.
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003): Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
3. Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D (2004): Caudate nucleus: Influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 21:1497-1507.
4. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, Margouleff C, Eidelberg D (2002): Comparative analysis of striatal FDOPA uptake in Parkinson's disease: Ratio method versus graphical approach. J Nucl Med 43:1324-1330.
5. Eggers C, Hilker R, Burghaus L, Schumacher B, Heiss WD (2009): High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci 276:27-30.
6. Eidelberg D (2009): Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 32:548-557.
7. Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, Margouleff D, Moeller JR, Patlak CS, Fahn S (1993): Striatal 18F-dopa uptake: Absence of an aging effect. J Cereb Blood Flow Metab 13:881-888.
8. Gallagher CL, Bell B, Palotti M, Oh J, Christian BT, Okonkwo O, Sojkova J, Buyan-Dent L, Nickles RJ, Harding SJ, Stone CK, Johnson SC, Holden JE (2014): Anterior cingulate dopamine turnover and behavior change in Parkinson's disease. Brain Imaging Behav 6 December [Epub ahead of print].
9. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, Deuschl G, Heiss WD (2002): Monosymptomatic resting tremor and Parkinson's disease: A multitracer positron emission tomographic study. Mov Disord 17:782-788.
10. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005): Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 65:1716-1722.
11. Holtbernd F, Eidelberg D (2012): Functional brain networks in movement disorders: Recent advances. Curr Opin Neurol 25:392-401.
12. Holtbernd F, Gagnon JF, Postuma RB, Ma Y, Tang CC, Feigin A, Dhawan V, Vendette M, Soucy JP, Eidelberg D, Montplaisir J (2014): Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 82:620-627.
13. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D (2007a): Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 34:714-723.
14. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D (2007b): Changes in network activity with the progression of Parkinson's disease. Brain 130:1834-1846.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
16. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D (1996): Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37:1760-1765.
17. Jokinen P, Helenius H, Rauhala E, Bruck A, Eskola O, Rinne JO (2009): Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med 50:893-899.
18. Kaasinen V, Maguire RP, Hundemer HP, Leenders KL (2006): Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease. J Neurol 253:340-348.
19. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, Baudrexel S, Diederich NJ, Heiss WD, Hilker R (2010): Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74:885-892.
20. Kumakura Y, Vernaleken I, Buchholz HG, Borghammer P, Danielsen E, Grunder G, Heinz A, Bartenstein P, Cumming P (2010): Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiol Aging 31:447-463.
21. Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, Dhawan V, Eidelberg D (2008): Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 131:1373-1380.
22. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D (2010): Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 51:7-15.
23. Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D (2007): Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 27:597-605.
24. Moeller JR, Eidelberg D (1997): Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 120: 2197-2206.
25. Niethammer M, Eidelberg D (2012): Metabolic brain networks in translational neurology: Concepts and applications. Ann Neurol 72:635-647.
26. Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, Dhawan V, Eidelberg D (2013): Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 78:204-209.
27. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG (2004): Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61:919-925.
28. Parent A, Hazrati LN (1995): Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 20:128-154.
29. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ (2011): Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. Neuroimage 56:1463-1468.
30. Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ (2012): [(1)(8)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(1)(8)F]FDOPA and [(1)(1)C]DASB PET study in Parkinson's disease. Neuroimage 59:1080-1084.
31. Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, Mungai F, Marini P, Formiconi AR, Sorbi S, Pupi A (2012): Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 33:e229239
32. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O (2000): Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 57:470-475.
33. Spetsieris P, Ma Y, Peng S, Ko JH, Dhawan V, Tang CC, Eidelberg D (2013): Identification of disease-related spatial covariance patterns using neuroimaging data. J Vis Exp 76:e50319.
34. Spetsieris PG, Eidelberg D (2011): Scaled subprofile modeling of resting state imaging data in Parkinson's disease: Methodological issues. Neuroimage 54:2899-2914.
35. Tang C, Eckert T, Dhawan V, Eidelberg D (2008): Parkinson's Disease: Evidence for a Short Metabolic Preclinical Period. American Academy of Neurology (AAN) 60th Annual Meeting: Abstract Chicago, IL, April 12-19.
36. Tang CC, Poston KL, Dhawan V, Eidelberg D (2010a): Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 30:1049-1056.
37. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D (2010b): Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 9:149-158.
38. van Beilen M, Portman AT, Kiers HA, Maguire RP, Kaasinen V, Koning M, Pruim J, Leenders KL (2008): Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. Parkinsonism Relat Disord 14:224-228.
39. Weder BJ, Leenders KL, Vontobel P, Nienhusmeier M, Keel A, Zaunbauer W, Vonesch T, Ludin HP (1999): Impaired somatosensory discrimination of shape in Parkinson's disease: Association with caudate nucleus dopaminergic function. Hum Brain Mapp 8:1-12.
40. Wu P, Yu H, Peng S, Dauvilliers Y, Wang J, Ge J, Zhang H, Eidelberg D, Ma Y, Zuo C (2014): Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain 137:3122-3128.